The estimated Net Worth of John Steuart is at least $917 mil dollars as of 16 May 2019. John Steuart owns over 7,278 units of Natera Inc stock worth over $901,235 and over the last 9 years John sold NTRA stock worth over $15,774.
John has made over 3 trades of the Natera Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently John exercised 7,278 units of NTRA stock worth $901,235 on 16 May 2019.
The largest trade John's ever made was buying 83,752 units of Natera Inc stock on 19 June 2016 worth over $999,999. On average, John trades about 3,554 units every 41 days since 2015. As of 16 May 2019 John still owns at least 7,278 units of Natera Inc stock.
You can see the complete history of John Steuart stock trades at the bottom of the page.
John's mailing address filed with the SEC is 35 OAKVALE AVE., , BERKELEY, CA, 94705.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy, eRoelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: